NCT02601378View on ClinicalTrials.gov

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

PHASE1TerminatedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

January 7, 2022

Study Completion Date

January 7, 2022

Conditions
Uveal Melanoma
Interventions
DRUG

LXS196

LXS196 as a single agent

DRUG

LXS196 and HDM201

LXS196 in combination with HDM201

Trial Locations (6)

2145

Novartis Investigative Site, Westmead

10032

Columbia University Medical Center, New York

28050

Novartis Investigative Site, Madrid

75231

Novartis Investigative Site, Paris

2300 RC

Novartis Investigative Site, Leiden

0379

Novartis Investigative Site, Oslo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY